Quantinno Capital Management’s Encompass Health EHC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.54M Sell
74,575
-4,094
-5% -$424K 0.01% 1095
2026
Q1
$7.61M Sell
78,669
-6,501
-8% -$667K 0.01% 974
2025
Q4
$9.04M Sell
85,170
-18,576
-18% -$2.15M 0.02% 820
2025
Q3
$13.2M Buy
103,746
+24,598
+31% +$2.93M 0.04% 551
2025
Q2
$9.71M Buy
79,148
+16,497
+26% +$1.88M 0.04% 539
2025
Q1
$6.35M Buy
62,651
+39,632
+172% +$3.87M 0.04% 551
2024
Q4
$2.13M Buy
23,019
+7,497
+48% +$736K 0.02% 828
2024
Q3
$1.5M Buy
15,522
+3,717
+31% +$334K 0.02% 826
2024
Q2
$1.01M Buy
11,805
+5,402
+84% +$453K 0.02% 804
2024
Q1
$529K Buy
6,403
+332
+5% +$24.3K 0.01% 940
2023
Q4
$405K Buy
+6,071
New +$393K 0.01% 878
2023
Q1
Sell
-7,654
Closed -$458K 862
2022
Q4
$458K Buy
+7,654
New +$416K 0.03% 560

Other funds holding EHC

Quantinno Capital Management's EHC Position: Q2 2026 in Review

Quantinno Capital Management reduced its Encompass Health (EHC) stake by 5.2% in Q2 2026, selling an estimated $424K and leaving 74,575 shares worth $7.54M. The position accounts for 0.01% of the portfolio, ranked #1095.

Quantinno Capital Management first reported a position in EHC in Q4 2022 and has held it in 12 quarters since. The position peaked at $13.2M in Q3 2025. 597 funds tracked by Wall St. Rank hold EHC as of Q2 2026.

  • Quantinno Capital Management held 74,575 shares of Encompass Health worth $7.54M as of Q2 2026.
  • Quantinno Capital Management sold 4,094 Encompass Health shares in Q2 2026, an estimated $424K.
  • Encompass Health made up 0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #1095 holding.
  • Quantinno Capital Management first reported a position in Encompass Health in Q4 2022 and has held it in 12 quarters since.
  • Quantinno Capital Management's Encompass Health position peaked at $13.2M in Q3 2025.
  • 597 funds tracked by Wall St. Rank held Encompass Health as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.